{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:30:46Z","timestamp":1788582646260,"version":"build-2803163510"},"reference-count":31,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Anderson\u2013Fabry (or Fabry) disease is a rare lysosomal storage disorder caused by a functional deficiency of the enzyme alpha-galactosidase A. The partial or total defect of this lysosomal enzyme, which is caused by variants in the GLA gene, leads to the accumulation of glycosphingolipids, mainly globotriaosylceramide in the lysosomes of different cell types. The clinical presentation of Fabry disease is multisystemic and can vary depending on the specific genetic variants associated with the disease. To date, more than 1000 different variants have been identified in the human GLA gene, including missense and nonsense variants, as well as small and large insertions or deletions. The identification of novel variants in individuals exhibiting symptoms indicative of Fabry disease, expands the molecular comprehension of the GLA gene, providing invaluable insights to physicians in the diagnosis of the disease. In this article, we present the case of two members of the same family, mother and son, in whom a new pathogenic variant was identified. This variant has not been previously described in the literature and is not present in databases. The two family members presented with a number of typical clinical manifestations of the disease, including cornea verticillata, neuropathic pain, left ventricular hypertrophy, angiokeratomas and abdominal pain. The son, but not his mother, showed reduced alpha-galactosidase A activity, while high levels of Lyso-Gb3 in the blood, a specific substrate accumulation biomarker, were found in both. Sequencing of the GLA gene revealed the presence of a variant, c.484delT, which is characterised by the deletion of a single nucleotide, a thymine, in exon 3 of the gene. This results in a frameshift variant, which introduces a premature stop codon, thereby generating a truncated and consequently non-functional protein. Therefore, the clinical and laboratory data indicate that the novel p.W162Gfs*3 variant described herein is associated with the classical form of Fabry disease.<\/jats:p>","DOI":"10.3390\/ijms26020470","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T07:40:13Z","timestamp":1736322013000},"page":"470","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Identification of a Novel Pathogenic Variant of the GLA Gene Associated with a Classic Phenotype of Anderson\u2013Fabry Disease: A Clinical and Molecular Study"],"prefix":"10.3390","volume":"26","author":[{"given":"Irene","family":"Giacalone","sequence":"first","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigina","family":"Ruzzi","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Hospital \u201cRenzetti\u201d, 66034 Lanciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Anania","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Cuonzo","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Hospital \u201cRenzetti\u201d, 66034 Lanciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela Maria","family":"Marsana","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Mastrippolito","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Hospital \u201cRenzetti\u201d, 66034 Lanciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Francofonte","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bucco","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Hospital \u201cRenzetti\u201d, 66034 Lanciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"D\u2019Errico","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Olimpia","family":"Longo","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Hospital \u201cRenzetti\u201d, 66034 Lanciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Zizzo","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Iarlori","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Unit, Hospital \u201cRenzetti\u201d, 66034 Lanciano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Duro","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2470-7030","authenticated-orcid":false,"given":"Paolo","family":"Colomba","sequence":"additional","affiliation":[{"name":"Institute for Biomedical Research and Innovation (IRIB), National Research Council (CNR), 90146 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry\u2019s disease. Ceramidetrihexosidase deficiency","volume":"276","author":"Brady","year":"1967","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: Preclinical studies demonstrate the effectiveness of \u03b1-galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_3","first-page":"33","article-title":"\u03b1-galactosidase A deficiency: Fabry disease","volume":"Volume 37","author":"Scriver","year":"2001","journal-title":"The Metabolic and Molecular Basis of Inherited Disease"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/1873-3468.12104","article-title":"Lysosomal glycosphingolipid catabolism by acid ceramidase: Formation of glycosphingoid bases during deficiency of glycosidases","volume":"590","author":"Ferraz","year":"2016","journal-title":"FEBS Lett."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jmedgenet-2015-103486","article-title":"Time to treatment benefit for adult patients with Fabry disease receiving agalsidase \u03b2: Data from the Fabry Registry","volume":"53","author":"Ortiz","year":"2016","journal-title":"J. Med. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Duro, G., Zizzo, C., Cammarata, G., Burlina, A., Burlina, A., Polo, G., Scalia, S., Oliveri, R., Sciarrino, S., and Francofonte, D. (2018). Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease ?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123726"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/jmedgenet-2020-107338","article-title":"Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease","volume":"59","author":"Nowak","year":"2022","journal-title":"J. Med. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"100968","DOI":"10.1016\/j.gim.2023.100968","article-title":"Long-term safety and efficacy of pegunigalsidase alfa: A multicenter 6-year study in adult patients with Fabry disease","volume":"25","author":"Hughes","year":"2023","journal-title":"Genet. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Perretta, F., and Jaurretche, S. (2023). Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?. Healthcare, 11.","DOI":"10.3390\/healthcare11040449"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.2010.200188","article-title":"FOCUS study investigations. Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: The FOCUS study","volume":"97","author":"Caudron","year":"2011","journal-title":"Heart"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and causes of death in males and females with Fabry disease: Findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Amodio, F., Caiazza, M., Monda, E., Rubino, M., Capodicasa, L., Chiosi, F., Simonelli, V., Dongiglio, F., Fimiani, F., and Pepe, N. (2022). An Overview of Molecular Mechanisms in Fabry Disease. Biomolecules, 12.","DOI":"10.3390\/biom12101460"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00109-005-0656-2","article-title":"Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population","volume":"83","author":"Dobrovolny","year":"2005","journal-title":"J. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Duro, G., Anania, M., Zizzo, C., Francofonte, D., Giacalone, I., D\u2019Errico, A., Marsana, E.M., and Colomba, P. (2024). Diagnosis of Fabry Disease Using Alpha-Galactosidase A Activity or LysoGb3 in Blood Fails to Identify up to Two Thirds of Female Patients. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25105158"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.clinbiochem.2012.03.015","article-title":"Identification of a novel mutation in the alpha-galactosidase A gene in patients with Fabry disease","volume":"45","author":"Colomba","year":"2012","journal-title":"Clin. Biochem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Azevedo, O., Cordeiro, F., Gago, M.F., Miltenberger-Miltenyi, G., Ferreira, C., Sousa, N., and Cunha, D. (2021). Fabry Disease and the Heart: A Comprehensive Review. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22094434"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ahj.2020.04.006","article-title":"Group of investigators. Predictors of Fabry disease in patients with hypertrophic cardiomyopathy: How to guide the diagnostic strategy?","volume":"226","author":"Azevedo","year":"2020","journal-title":"Am. Heart J."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s-Saladelafont, E., Fern\u00e1ndez-Mart\u00edn, J., and Ortolano, S. (2023). Fabry Disease and Central Nervous System Involvement: From Big to Small, from Brain to Synapse. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24065246"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease\u2014A comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e160041","DOI":"10.1177\/2326409816666298","article-title":"A 15-Year Perspective of the Fabry Outcome Survey","volume":"4","author":"Giugliani","year":"2016","journal-title":"J. Inborn Errors Metab. Screen."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gene.2015.12.024","article-title":"Molecular and clinical studies in five index cases with novel mutations in the GLA gene","volume":"578","author":"Zizzo","year":"2016","journal-title":"Gene"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1023\/A:1012993305223","article-title":"Anderson-Fabry disease: Clinical manifestations of disease in female heterozygotes","volume":"24","author":"Whybra","year":"2001","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J. Med. Genet."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","article-title":"Fabry Registry. Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry","volume":"93","author":"Wilcox","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0009-8981(01)00478-8","article-title":"Fabry disease: Enzymatic diagnosis in dried blood spots on filter paper","volume":"308","author":"Chamoles","year":"2001","journal-title":"Clin. Chim. Acta"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1515\/cclm-2016-0340","article-title":"Diagnosis of sphingolipidoses: A new simultaneous measurement of lysosphingolipids by LC-MS\/MS","volume":"55","author":"Polo","year":"2017","journal-title":"Clin. Chem. Lab. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/470\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:24:56Z","timestamp":1759919096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ijms26020470"],"URL":"https:\/\/doi.org\/10.3390\/ijms26020470","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]}}}